Head and neck cancer (HNC) is a fatal malignancy with an overall long-term survival of
about 50% for all stages. The diagnosis is not rarely delayed, and the majority of patients …

While a large proportion of patients presenting with stage I and II squamous cell carcinoma
of the head and neck (SCCHN) will remain disease free after single modality treatment, the …

Simple Summary Immunotherapy has made a breakthrough in the treatment of patients with
recurrent and/or metastatic head and neck squamous cell carcinoma in the second line …

Recurrent and metastatic squamous cell carcinoma of the head and neck still carries a poor
prognosis. Response rates with combination chemotherapy regimens are generally higher …

Simple Summary Head and neck squamous cell carcinoma (HNSCC), in the locally
advanced setting, relapses in more than 50% of cases after surgery and/or chemo …

Background: Head and neck squamous cell carcinoma (HNSCC) is the most common
malignant cancer occurring in the head and neck area, approximately 90% of the cases …

Introduction: The majority of patients with locally advanced head and neck squamous cell
carcinoma (HNSCC) will recur. The treatment of patients with recurrent/metastatic (R/M …

The major development of the past decade in the first-line treatment of recurrent and/or
metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) was the …

Immunotherapy has revolutionized cancer treatment in the past 2 decades, mostly with
immune checkpoint blockade approaches. In squamous cell carcinoma of the head and …

Background The most effective regimen is unclear for patients with recurrent or metastatic
head and neck squamous cell carcinomas (R/M HNSCC). We performed a systematic …